FDA Inspection 1016106 — Adamas Pharmaceuticals, Inc.
The FDA completed an inspection of Adamas Pharmaceuticals, Inc. on April 26, 2017 in Emeryville, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 26, 2017
- Fiscal Year
- 2017
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Emeryville, CA (United States)
Additional Details
Sponsor, Contract Research Organization